Alvotech (ALVO) Jefferies Global Healthcare Conference 2026 summary

Company overview and strategic positioning

• Built a fully integrated, end-to-end biosimilar platform since 2013, investing $2 billion, with five products on the market globally and two in the U.S., aiming for five in the U.S. by year-end.

• Commercial infrastructure spans over 90 countries, positioning the company at an inflection point for growth.

• Strategic advantage lies in a dedicated in-house biosimilar platform and a robust pipeline.

Regulatory progress and remediation

• Recently resubmitted BLAs to the FDA for biosimilars of Simponi and Eylea ahead of schedule, with launches expected by year-end.

• Addressed FDA CRL observations by upgrading the Iceland facility, implementing over 200 CAPAs, and strengthening complaint processes.

• Facility has passed multiple FDA inspections in 2024, reflecting successful remediation.

• Prolia resubmission is imminent, with the partner holding U.S. marketing authorization.

Manufacturing and partnerships

• New partnership with Fujifilm expands manufacturing capacity in the U.S. and U.K., supporting both commercial and pipeline products.

• Incremental capacity from Fujifilm expected to come online after mid-2025.

• Additional capacity is needed due to a broader-than-expected pipeline and multiple upcoming launches.